Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The SARS-CoV-2 infection in the airway epithelium induces cytopathic effects and the cessation of ciliary movement. Increased cytokines and chemokines have been reported to be associated with the severity of the disease. However, most of the molecular and cellular aspects of the inflammatory response and the processes of development of humoral and cellular immunity in these patients are unknown. The aim of this study is characterizing inflammatory processes, seeking to expand the knowledge of the cellular and molecular pathophysiology of COVID-19 that could help in the decision-making of treating health personnel. Mainly, the study is focused on analyzing the inflammatory response by determining cytokines and chemokines. Also, the viral load of the patients with COVID-19 will be determined and will be correlated with the antibody titers. On the other hand, cells will be immunophenotyped to search the cellular depletion profile. Finally, an epidemiological analysis of the patients will be carried out.
Description: Pg/ml of IL-2, CXCL8 / IL-8,IL-4, CCL5 / RANTES, IL-6, CXCL9 / MIG, IL-10, CCL2 / MCP-1, TNF-alfa, CXCL10 / IP-10, IFN-alfa, soluble receptor IL6, IFN-gamma.
Measure: Serum levels of cytokines and chemokines Time: Day 0Description: Pg/ml of IL-2, CXCL8 / IL-8,IL-4, CCL5 / RANTES, IL-6, CXCL9 / MIG, IL-10, CCL2 / MCP-1, TNF-alfa, CXCL10 / IP-10, IFN-alfa, soluble receptor IL6, IFN-gamma.
Measure: Serum levels of cytokines and chemokines Time: Day 3Description: Pg/ml of IL-2, CXCL8 / IL-8,IL-4, CCL5 / RANTES, IL-6, CXCL9 / MIG, IL-10, CCL2 / MCP-1, TNF-alfa, CXCL10 / IP-10, IFN-alfa, soluble receptor IL6, IFN-gamma.
Measure: Serum levels of cytokines and chemokines Time: Day 7Description: log10 U/ml
Measure: Viral load Time: Day 0Description: log10 U/ml
Measure: Viral load Time: Day 7Description: Immunophenotypic profile of myeloid cells in COVID by surface molecules CD45, CD14, CD16, mIL-6R, CD73 and CD3. reported in relative fluorescence units and relative percentage of cells analyzed by flow cytometry
Measure: Immunophenotype of myeloid cells Time: Day 0Description: Immunophenotypic profile of myeloid cells in COVID by surface molecules CD45, CD14, CD16, mIL-6R, CD73 and CD3. reported in relative fluorescence units and relative percentage of cells analyzed by flow cytometry
Measure: Immunophenotype of myeloid cells Time: Day 3Description: Immunophenotypic profile of myeloid cells in COVID by surface molecules CD45, CD14, CD16, mIL-6R, CD73 and CD3. reported in relative fluorescence units and relative percentage of cells analyzed by flow cytometry
Measure: Immunophenotype of myeloid cells Time: Day 7Description: relative absorbance units by ELISA
Measure: RBD-SARS-CoV Protein S- antibodies Time: Day 0Description: relative absorbance units by ELISA
Measure: RBD-SARS-CoV Protein S- antibodies Time: Day 3Description: relative absorbance units by ELISA
Measure: RBD-SARS-CoV Protein S- antibodies Time: Day 7Description: Cell count per area (/ mm2) of immune cell sub-populations
Measure: Analysis of cellular immune response Time: Day 0Description: Cell count per area (/ mm2) of immune cell sub-populations
Measure: Analysis of cellular immune response Time: Day 3Description: Cell count per area (/ mm2) of immune cell sub-populations
Measure: Analysis of cellular immune response Time: Day 7Description: Immunophenotypic profile of stem cells and progenitor cells populations COVID by surface molecules CD34, CD38, CD45RA, Lin, CD3, CD8, CD56, CD19, CD20, CD11b, CD235a andCD14. reported in relative fluorescence units and relative percentage of cells, analyzed by flow cytometry
Measure: Hematopoietic stem cells and progenitor cells populations in peripheral blood Time: Day 0Description: Immunophenotypic profile of stem cells and progenitor cells populations COVID by surface molecules CD34, CD38, CD45RA, Lin, CD3, CD8, CD56, CD19, CD20, CD11b, CD235a andCD14. reported in relative fluorescence units and relative percentage of cells, analyzed by flow cytometry
Measure: Hematopoietic stem cells and progenitor cells populations in peripheral blood Time: Day 3Description: Immunophenotypic profile of stem cells and progenitor cells populations COVID by surface molecules CD34, CD38, CD45RA, Lin, CD3, CD8, CD56, CD19, CD20, CD11b, CD235a andCD14. reported in relative fluorescence units and relative percentage of cells, analyzed by flow cytometry
Measure: Hematopoietic stem cells and progenitor cells populations in peripheral blood Time: Day 7Description: Questionnaire
Measure: Questionnaire of Sociodemographic, labor, pathological and personal characteristics Time: Day 0Description: Is used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems.
Measure: SOFA (Secuential Organ Failure Assessment Score) Time: Day 0Description: Is used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems.
Measure: SOFA (Secuential Organ Failure Assessment Score) Time: Day 3Description: Is used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems.
Measure: SOFA (Secuential Organ Failure Assessment Score) Time: Day 7Description: mg/dL
Measure: Fibrinogen Time: Day 0Description: mg/dL
Measure: Fibrinogen Time: Day 3Description: mg/dL
Measure: Fibrinogen Time: Day 7Description: mg/L
Measure: C-Reactive protein Time: Day 0Description: mg/L
Measure: C-Reactive protein Time: Day 3Description: mg/L
Measure: C-Reactive protein Time: Day 7Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports